Navigation Links
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
Date:1/15/2014

ffairs. He began his industry career at Somatix Therapy Corporation as a Research Scientist. Dr Reynolds gained his MD at Stanford University, where he subsequently conducted postdoctoral research. He also holds a PhD in Biophysics from Stanford University, and a degree in Chemistry from Dartmouth College.

About Oxford BioTherapeutics

Oxford BioTherapeutics is developing a range of antibody-drug conjugates for cancer, based on its OGAP® oncology targeting technology. The OGAP® system incorporates one of the world's largest proprietary proteomic databases, with data on 7,500 cancer cell proteins providing unique, highly-qualified therapeutic targets. The company has established collaborations with leading antibody and cancer toxin technology companies, including Seattle Genetics, to build an in-house pipeline of antibody-drug conjugates (ADCs) against a number of these novel targets. In 2012, Oxford BioTherapeutics entered a strategic agreement to accelerate the development of its ADCs, with partner Menarini providing clinical and manufacturing expertise and investment of up to $1 billion in exchange for commercial rights to the treatments outside the US and Japan.

Oxford BioTherapeutics is based in Oxford, UK and San Jose, CA, and has a strong management team with significant experience of developing antibody-based therapies. The company has completed a number of funding rounds, and is supported by a syndicate of specialist venture capital investors. For more information please visit http://www.oxfordbiotherapeutics.com.

Contacts
Dr Christian Rohlff
CEO
Oxford BioTherapeutics
+44(0)1235-861770
christian.r@oxfordbiotherapeutics.com

David Dible / Sita Shah'/>"/>

SOURCE Oxford BioTherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxford University Press to publish BioScience journal starting in 2014
2. Oxford BioMedica Announces Update from ARVO 2013
3. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
4. Oxford Performance Materials and Biomet Microfixation Join Forces
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Finance Completes $271.4 Million Securitization Transaction
7. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
8. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Santa Paula, CA (PRWEB) September 15, 2014 ... of long term implantable silicones for the medical ... strength, responsive silicone gel for the implantable medical ... incorporates a unique crosslink technology delivering a silicone ... adhesion. The Dual Matrix technology consists of ...
(Date:9/15/2014)... September 15, 2014 Hydro Dynamics, ... announced today that it will be partnering with ... ( http://www.proteaf.com ) for implementing its Shock Wave ... continuous processing. Continuous flow chemistry through process ... pharmaceutical and petrochemical markets for decades. The ...
(Date:9/12/2014)... magnet using an electric field (magnetoelectric memory [MEM] ... next-generation technology for information processing and storage. Multiferroic ... due to the coexistence of electric and magnetic ... spontaneous electric and magnetic polarizations is rare in ... the MEM effect. This article briefly reviews a ...
(Date:9/12/2014)... -- On Thursday, September 11, 2014, the NASDAQ ... Average finished the day 0.12% lower at 17,049.00, and the ... broad based as seven out of ten sectors ended the ... ended the day at 741.83, down 0.33%, while the index ... initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... Oct. 31, 2011 Reportlinker.com announces that ... in its catalogue: US ... http://www.reportlinker.com/p0397796/US-Intranasal-Drug-Delivery-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology This report ... Delivery in US$ Million by the following ...
... iBio, Inc. (NYSE AMEX: IBIO ) ... Patent and Trademark Office for US Patent 8,058,511, entitled ... extends iBio,s patent coverage of viral vectors comprising its ... developed by scientists at iBio,s research collaborator, the Fraunhofer ...
... BETHESDA, Md., Oct. 28, 2011 , ... innovator in biotechnology for therapy in diabetes, metabolic syndrome ... services to food, supplement, biotechnology and pharmaceutical companies – ... sell $1.25 million of shares of its common stock ...
Cached Biology Technology:US Intranasal Drug Delivery Industry 2US Intranasal Drug Delivery Industry 3US Intranasal Drug Delivery Industry 4US Intranasal Drug Delivery Industry 5US Intranasal Drug Delivery Industry 6US Intranasal Drug Delivery Industry 7US Intranasal Drug Delivery Industry 8US Intranasal Drug Delivery Industry 9US Intranasal Drug Delivery Industry 10iBio Announces New US Patent for iBioLaunchâ„¢ Technology 2iBio Announces New US Patent for iBioLaunchâ„¢ Technology 3Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 2Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 3
(Date:9/15/2014)... carbon-halogen bonds are produced naturally across all kingdoms of ... with a broad range of biological activities. The presence ... profound influence on their molecular properties. , ... been to find the late-stage, site-specific incorporation of a ... an sp C-H bond (one of the most inert ...
(Date:9/15/2014)... vision document, released today by the National Academy ... goals, objectives, and strategies for the program and ... next five years (2015-2020). In addition, the ... be funded in 2015, will include exploratory grants, ... , The $500 million, 30-year program to be ...
(Date:9/15/2014)... Research suggests that genes that affect hearing and cognitive ... the ability to understand and perceive rhythm, pitch, timbre, ... authors of a BioEssays article explain that ... within a population, with the majority of individuals having ... a complex trait attributable to several underlying genes, and ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... about Arctic climate variation during an ancient episode of ... climate variability in the greenhouse world of the Late ... probably would not greatly change the climatic influence associated ... the El Nio Southern Oscillation (ENSO) or ...
... Springer journals Frontiers of Medicine and Protein ... important literature database for medical and biomedical articles, in January. ... publishing partner Higher Education Press. Both journals are part of ... 90 Springer journals. Frontiers in Medicine has a ...
... Ancient stone faces carved into the walls of a well-known ... searching for fossils of extinct giant rats., The team of archaeologists ... tip of East Timor. "Looking up from the cave floor ... on what seemed to be a weathered carving," CSIRO,s Dr Ken ...
Cached Biology News:Arctic climate variation under ancient greenhouse conditions 2Arctic climate variation under ancient greenhouse conditions 3Research literature from China listed in Medline 2Giant rats lead scientists to ancient face carvings 2
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
RABBIT ANTI D-TYROSINE CONJUGATE...
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: